Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?
about
Utilizing population variation, vaccination, and systems biology to study human immunologyModel answers or trivial pursuits? The role of mathematical models in influenza pandemic preparedness planningFactors influencing infection by pandemic influenza A(H1N1)pdm09 over three epidemic waves in Singapore.Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.Influenza immunology evaluation and correlates of protection: a focus on vaccines.Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study.Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients.[Concepts, effectiveness, and perspectives of pandemic and seasonal influenza vaccines].Risk factors for influenza among health care workers during 2009 pandemic, Toronto, Ontario, CanadaBaseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines.Influence of prior influenza vaccination on antibody and B-cell responses.Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study.Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strainsSerological response in RT-PCR confirmed H1N1-2009 influenza a by hemagglutination inhibition and virus neutralization assays: an observational study.A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes.Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residentsDiscordant correlation between serological assays observed when measuring heterosubtypic responses against avian influenza H5 and H7 viruses in unexposed individuals.The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus.The Split Virus Influenza Vaccine rapidly activates immune cells through Fcγ receptors.Serological response to influenza vaccination among children vaccinated for multiple influenza seasonsAntibody landscapes after influenza virus infection or vaccination.Characterization of influenza vaccine immunogenicity using influenza antigen microarrays.Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults ≥ 50 years of age in MexicoQuantitative review of antibody response to inactivated seasonal influenza vaccines.Factors associated with maintenance of antibody responses to influenza vaccine in older, community-dwelling adults.Effect of Antihelminthic Treatment on Vaccine Immunogenicity to a Seasonal Influenza Vaccine in Primary School Children in Gabon: A Randomized Placebo-Controlled Trial.Vulnerability, distress, and immune response to vaccination in older adults.Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection.Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.Fluarix, inactivated split-virus influenza vaccine.Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adultsImpaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.Influenza vaccine response in adults exposed to perfluorooctanoate and perfluorooctanesulfonate.Reduced-dose influenza vaccine.Rituximab-treated patients have a poor response to influenza vaccinationNanotools for megaproblems: probing protein misfolding diseases using nanomedicine modus operandiEffects of influenza immunization on humoral and cellular alloreactivity in humansImpact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipientsApoptosis and other immune biomarkers predict influenza vaccine responsiveness.
P2860
Q26799374-426D178A-EB47-4AB4-BFD1-6BD8A845746EQ30230076-B7FB96E2-368A-4DC6-84C5-AB57C7635521Q30351890-1B591FEC-0752-4BC9-9614-329BDAFFAE01Q30357144-A76110DF-263C-4C1C-A2F1-1E6B0E14E380Q30385397-12A1EF4B-32A4-42DC-8340-43B98A7C85AFQ30405315-069B4134-C0B4-4627-A9D0-3FCAA5E2AF6AQ30420230-28679FB6-4046-47F9-A73A-34C9ABDCA6CBQ30425269-A49C79D2-9F82-4FBA-B509-3A19BF94F60CQ30429951-21418C19-2D64-4108-BD12-7BA617C4156DQ33348541-39EEA328-947B-4BE9-A149-A4CD35B98267Q33361605-4E962C18-3413-42C3-98EF-E66785F01890Q33538308-4C3D4A8A-8E83-4F6E-BECE-52BB2762C9DAQ33588044-3C928507-C5D3-4480-A0E3-3311E2DAC393Q33655279-CEDE2B78-AACD-4D30-B849-EDD4C28C5563Q33683361-AC81AEE8-A9DA-46B5-A375-160AEA35F629Q33712709-0A65E7F1-1186-4342-90E8-0F2D7CEE3F60Q33760887-815EC609-F571-4E32-9A4A-54892002C259Q33809686-6543D503-AB12-42A6-A706-7FCCF3CAF22FQ34097791-3BC9A3B6-109A-4CD5-B36A-B9792552D6DFQ34313957-B53A64F4-385B-4AD2-B5C3-46A18ACCB289Q34512411-7AFC072B-C96F-4B12-A2A4-626CA72416EDQ34580640-9242A3DA-4A0F-451B-9751-E41644BBE600Q34755553-A5A3A5AF-C829-4296-9205-6F87A10BC0BDQ35021112-2867821B-967A-4696-B972-B0C500F4989AQ35218808-CAA324FE-07B8-466A-9F65-7E81C6C3EA2DQ35555742-746D14EE-0672-470E-9DDE-6B0EEC180399Q35656728-7D7AE6E2-9187-4297-85E0-93D88644FE31Q35830791-D4035EE1-8386-422C-90AC-C92365F9C9FAQ35887739-FC19E929-4E55-44A3-9F69-9B0AFA7E1689Q36306922-0DEF1C52-8A54-48D6-8534-36ABADF91A43Q36407258-A30FC16E-19B2-4909-A427-661806988EC6Q36452409-495DAD23-8032-45FF-91D2-0AE5F813EE07Q36488282-CEBFD4EC-1B4A-4981-B88F-F714C4688193Q36493907-87147C80-A758-4F2A-AFB2-46A23216DE2DQ36533701-CF5300D5-5B75-4327-BFC6-1E6520EEAA17Q36589247-09C38708-3A27-4187-9176-F964AB4BD67FQ36615206-D0D41C9A-C556-4705-BB76-BB289481FC43Q36661931-B1EB586B-C78B-4378-9793-7B4806F6B5B5Q36832305-6E9432A9-4BC7-4B39-AA54-9BBFAB003689Q36856669-D5F88D82-A967-43DD-B42B-2FDAF7945423
P2860
Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Seroprotection rate, mean fold ...... onse to influenza vaccination?
@en
Seroprotection rate, mean fold ...... onse to influenza vaccination?
@nl
type
label
Seroprotection rate, mean fold ...... onse to influenza vaccination?
@en
Seroprotection rate, mean fold ...... onse to influenza vaccination?
@nl
prefLabel
Seroprotection rate, mean fold ...... onse to influenza vaccination?
@en
Seroprotection rate, mean fold ...... onse to influenza vaccination?
@nl
P2093
P1433
P1476
Seroprotection rate, mean fold ...... onse to influenza vaccination?
@en
P2093
P304
P356
10.1016/J.VIRUSRES.2004.02.024
P577
2004-07-01T00:00:00Z